EP1210366A1 - Homologues d'une proteine pneumococcique et fragments pour vaccins - Google Patents

Homologues d'une proteine pneumococcique et fragments pour vaccins

Info

Publication number
EP1210366A1
EP1210366A1 EP00959433A EP00959433A EP1210366A1 EP 1210366 A1 EP1210366 A1 EP 1210366A1 EP 00959433 A EP00959433 A EP 00959433A EP 00959433 A EP00959433 A EP 00959433A EP 1210366 A1 EP1210366 A1 EP 1210366A1
Authority
EP
European Patent Office
Prior art keywords
polypeptide
group
sequence
polypeptides
isolated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP00959433A
Other languages
German (de)
English (en)
Inventor
Scott Koenig
Jon Heinrichs
Leslie Sydnor Johnson
John E. Adamou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MedImmune LLC
Original Assignee
MedImmune LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MedImmune LLC filed Critical MedImmune LLC
Publication of EP1210366A1 publication Critical patent/EP1210366A1/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Definitions

  • Staphylococcus aureus and Staphylococcus epidermidis readily colonize the skin of healthy individuals and can cause acute disease in patients following immunosuppression or traumatic injury. Infections caused by these species include bacteremia, endocarditis, osteomyelitis, wound infections and infections associated with indwelling catheters.
  • Streptococcus pneumoniae is a gram positive bacterium that is a major causative agent in invasive infections in animals and humans, such as the aforementioned sepsis, meningitis, and otitis media, as well as lobar pneumonia (Tuomanen, et al. New England J. of Medicine 322: 1280-1 284 ( 1 995)).
  • pneumococci readily bind to non- inflamed human epithelial cells of the upper and lower respiratory tract by binding to eukaryotic carbohydrates in a lectin-like manner (Cundell et al. , Micro. Path. 17:361 -374 (1 994)).
  • the present invention is also directed to novel genes, and the polypeptides encoded thereby, derived from gram positive bacteria other than S. pneumoniae, and which bear sequence homology to the Sp36 gene already described.
  • gram positive bacteria include the group A and B streptococci, as described herein, as well as species of the genus Staphylococcus, especially S. aureus.
  • Figures 1 shows the results of a Southern blot of genomic DNA from S. aureus, S. pyogenes, and pneumococcus.
  • the DNA was digested with restriction nucleases -5at7?HI or PvuW, and after electrophoresis and transfer to a nylon membrane, was probed with a labeled DNA fragment encompassing the pneumococcal gene encoding Sp36.
  • the hybridization and washes were carried out under low stringency conditions.
  • the results show hybridization by the labeled probe to a S. aureus fragment in both the BamH ⁇ and Pvull lanes and to two fragments in the PvuW digests of two strains of S. pyogenes.
  • Figure 3 shows the results of a Southern blot of genomic DNA from S. pyogenes, S. agalactiae, and S. pneumoniae probed with DNA encoding the full length Sp36 homolog from S. pyogenes. The hybridization was carried out under low stringency conditions. These results demonstrate that the S. pyogenes Sp36 homolog, used as a probe, is capable of detecting a homologous gene in S. agalactiae and pneumococcus.
  • the present invention also relates to such polynucleotides and polypeptides in enriched, preferably isolated, or even purified, form.
  • coding region refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.
  • the coding region can be from a normal, mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.
  • primer means a short nucleic acid sequence that is paired with one strand of DNA and provides a free 3'OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.
  • promoter means a region of DNA involved in binding of RNA polymerase to initiate transcription.
  • the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period.
  • polypeptides of the present invention may be a naturally purified product, or a product of chemical synthetic procedures, or produced by recombinant techniques from a prokaryotic or eukaryotic host (for example, by bacterial, yeast, higher plant, insect and mammalian cells in culture). Depending upon the host employed in a recombinant production procedure, the polypeptides of the present invention may be glycosylated or may be non-glycosylated. Polypeptides of the invention may also include an initial methionine amino acid residue.
  • Antibodies specific for the polypeptides disclosed herein may be either polyclonal or monoclonal and may even be in the form of antisera.
  • they may be produced by conventional methods of preparing monoclonal antibodies, such as from conventional hybridoma cells, and may also be produced by genetically engineered cells transformed with vectors containing genes specifically coding for the different heavy and light chains of antibody molecules having an arrangement of variable regions specifically complementary to one or more of the polypeptides of the invention.
  • Such recombinantly produced antibodies may be in the form of either dimers or tetramers, depending on the type of cellular expression system utilized therefor.
  • GAS36 SEQ ID NO: 2
  • GAS36(2) SEQ ID NO: 4
  • GBS36 SEQ ID NO: 6

Abstract

La présente invention concerne des polypeptides isolés présentant une homologie de séquence avec la protéine Sp36 trouvée dans des organismes pneumococciques tels que Streptococcus pneumoniae. L'invention concerne également des polynucléotides codant de tels polypeptides. L'invention concerne aussi des anticorps spécifiques des polypeptides de l'invention et l'utilisation de tels anticorps pour le traitement d'affections imputables aux staphylocoques ainsi qu'aux streptocoques des groupes A et B. L'invention concerne enfin l'utilisation des polypeptides de l'invention dans des compositions et en tant que vaccins, ainsi que leur utilisation prophylactique notamment pour la vaccination d'animaux, spécialement des humains, contre une grande variété d'affections à streptocoques, à staphylocoques et autres.
EP00959433A 1999-08-25 2000-08-25 Homologues d'une proteine pneumococcique et fragments pour vaccins Ceased EP1210366A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15075099P 1999-08-25 1999-08-25
US150750P 1999-08-25
PCT/US2000/023417 WO2001014421A1 (fr) 1999-08-25 2000-08-25 Homologues d'une proteine pneumococcique et fragments pour vaccins

Publications (1)

Publication Number Publication Date
EP1210366A1 true EP1210366A1 (fr) 2002-06-05

Family

ID=22535847

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00959433A Ceased EP1210366A1 (fr) 1999-08-25 2000-08-25 Homologues d'une proteine pneumococcique et fragments pour vaccins

Country Status (5)

Country Link
EP (1) EP1210366A1 (fr)
JP (1) JP4749641B2 (fr)
AU (1) AU7076100A (fr)
CA (1) CA2382795A1 (fr)
WO (1) WO2001014421A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7128918B1 (en) 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
US7074415B2 (en) 2000-06-20 2006-07-11 Id Biomedical Corporation Streptococcus antigens
WO2002083855A2 (fr) 2001-04-16 2002-10-24 Wyeth Holdings Corporation Nouveaux cadres de lecture ouverts de streptococcus pneumoniae codant pour des antigenes polypeptidiques, et leurs utilisations
FR2824074A1 (fr) * 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
WO2003054007A2 (fr) 2001-12-20 2003-07-03 Shire Biochem Inc. Antigenes de streptococcus
US8729013B2 (en) 2004-08-26 2014-05-20 The University Of Western Ontario Methods of inhibiting staphylobactin-mediated iron uptake in S. aureus
GB201003920D0 (en) * 2010-03-09 2010-04-21 Glaxosmithkline Biolog Sa Method of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69737125T3 (de) * 1996-10-31 2015-02-26 Human Genome Sciences, Inc. Streptococcus pneumoniae-Antigene und Impfstoffe
TR200002437T2 (tr) * 1998-02-20 2000-11-21 Biochem Pharma Inc. B grubu streptococcus antijenleri.
EP1100920A2 (fr) * 1998-07-27 2001-05-23 Microbial Technics Limited Acides nucleiques et proteines de streptococcus groupe b

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0114421A1 *

Also Published As

Publication number Publication date
CA2382795A1 (fr) 2001-03-01
AU7076100A (en) 2001-03-19
JP4749641B2 (ja) 2011-08-17
WO2001014421A1 (fr) 2001-03-01
JP2003507054A (ja) 2003-02-25

Similar Documents

Publication Publication Date Title
EP2050464B1 (fr) Protéines de streptococcus pneumoniae et fragments immunogènes pour vaccins
EP2261358B1 (fr) Antigènes de Streptococcus
AU777856B2 (en) Streptococcus pneumoniae proteins and vaccines
US6863893B2 (en) Derivatives of choline binding proteins for vaccines
KR100771148B1 (ko) 그룹 ｂ 스트렙토코커스 항원
EP1456231A2 (fr) Antigenes de streptococcus
US6689369B2 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EP1297145B1 (fr) Antigenes de streptococcus pyogenes
US6833356B1 (en) Pneumococcal protein homologs and fragments for vaccines
AU2001255772A1 (en) Immunogenic pneumococcal protein and vaccine compositions thereof
EP1210366A1 (fr) Homologues d'une proteine pneumococcique et fragments pour vaccins
US6887480B1 (en) Streptococcus pneumoniae proteins and vaccines
AU2004242430B2 (en) Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
EP1950302B1 (fr) Nouveaux antigènes de streptocoque

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020222

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MEDIMMUNE, INC.

17Q First examination report despatched

Effective date: 20050301

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20070625